Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Pozenveo (poziotinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Assertio, Hanmi, Luye Group

Drug class:

HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab (18)

mobocertinib (12)

trastuzumab-dttb (11)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Zercepac (trastuzumab biosimilar) (8)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 exon 20 mutation	Non Small Cell Lung Cancer	HER-2 exon 20 mutation	Non Small Cell Lung Cancer	poziotinib Sensitive: B - Late Trials poziotinib Sensitive : B	poziotinib Sensitive: B - Late Trials poziotinib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 YVMA	Lung Cancer	HER-2 YVMA	Lung Cancer	HER2-targeted CAR-T immunotherapy + poziotinib Sensitive: C2 – Inclusion Criteria HER2-targeted CAR-T immunotherapy + poziotinib Sensitive : C2	HER2-targeted CAR-T immunotherapy + poziotinib Sensitive: C2 – Inclusion Criteria HER2-targeted CAR-T immunotherapy + poziotinib Sensitive : C2
HER-2 positive	Non Small Cell Lung Cancer	HER-2 positive	Non Small Cell Lung Cancer	poziotinib Sensitive: C3 – Early Trials poziotinib Sensitive : C3	poziotinib Sensitive: C3 – Early Trials poziotinib Sensitive : C3
HER-2 G778_P780dup	Non Small Cell Lung Cancer	HER-2 G778_P780dup	Non Small Cell Lung Cancer	poziotinib Sensitive: C3 – Early Trials poziotinib Sensitive : C3	poziotinib Sensitive: C3 – Early Trials poziotinib Sensitive : C3
EGFR L858R + EGFR M766Q	Lung Adenocarcinoma	EGFR L858R + EGFR M766Q	Lung Adenocarcinoma	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
HER-2 V777L + EGFR L858R	Lung Cancer	HER-2 V777L + EGFR L858R	Lung Cancer	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
ABCB1 overexpression	Ovarian Cancer	ABCB1 overexpression	Ovarian Cancer	lapatinib + poziotinib Sensitive: D – Preclinical lapatinib + poziotinib Sensitive : D	lapatinib + poziotinib Sensitive: D – Preclinical lapatinib + poziotinib Sensitive : D
HER-2 G778_P780dup	Breast Cancer	HER-2 G778_P780dup	Breast Cancer	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
HER-2 T862A + HER-2 L755S	Breast Cancer	HER-2 T862A + HER-2 L755S	Breast Cancer	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D